Insulet Corporation (PODD)
Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insulet (PODD) Q4 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago.
Insulet beats quarterly profit estimates on insulin pump demand
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Here's Why You Should Add PODD Stock to Your Portfolio Now
Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.
PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU
Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.
Heavy Interest in Insulet's Insulin Delivery Device
Sales are surging for Insulet Corporation (PODD).
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain Insulet Stock in Your Portfolio Now?
PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.
Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massachusetts federal court on Thursday.
Here's Why Insulet (PODD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.
